(✱,✱)vahid007.nft (💙,🧡)(🍊,💊) "(🧙♂️,🧙♂️)"
3.9K posts

(✱,✱)vahid007.nft (💙,🧡)(🍊,💊) "(🧙♂️,🧙♂️)"
@VShams
@IntractAmbassador gnoma


One month of the Iran War, in Economist covers










🩺 Community Question: In medical innovation, what drives greater long-term impact: U.S.-grade quality for rigorous validation and strict regulation or Asia-speed execution for faster approvals and rapid scale? Viewpoint A: U.S.-Grade Quality Through institutions like the U.S. Food and Drug Administration, the U.S. emphasizes deep clinical validation before approval. Rigor reduces risk, protects trust, and supports durable breakthrough innovation. Viewpoint B: Asia-Speed Execution Countries such as China and India accelerate approvals and deploy innovations at scale. Faster access can save lives, especially in high-burden diseases. 👇 Drop A or B and share your perspective.
















